



Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code 股份代號 : 1889



INTERIM REPORT 中期報告 **2020**

BOARD OF DIRECTORS

Executive Directors

Mr. Chen Chengqing (*Chairman*)

Professor Zhang Rongqing

Mr. Gao Borui

(*appointed with effect from 26 July 2019*)

Mr. Yuan Chaoyang

(*appointed with effect from 26 July 2019*)

Mr. She Hao

(*appointed with effect from 11 November 2019*)

Mr. Cheng Hoi Kai, Frederick

(*appointed with effect from 9 May 2019 and
resigned with effect from 1 November 2019*)

Ms. Hung Hoi Lan

(*resigned with effect from 26 July 2019*)

Non-executive Director

Mr. Xiu Yuan

Independent Non-executive Directors

Professor Zhu Yi Zhun

(*appointed with effect from 31 December 2020*)

Mr. Khor Khie Liem Alex

(*appointed with effect from 3 February 2021*)

Mr. Zhang Ruigen

(*appointed with effect from 25 June 2021*)

Mr. Chan Chung Yin, Victor

(*resigned with effect from 3 April 2019*)

Mr. Tu Fangkui

(*resigned with effect from 30 June 2020*)

Mr. Wang Zihao

(*resigned with effect from 24 November 2020*)

Mr. Long Jun

(*resigned with effect from 30 November 2020*)

董事會

執行董事

陳成慶先生 (*主席*)

張榮慶教授

高伯瑞先生

(*自二零一九年七月二十六日起獲委任*)

袁朝陽先生

(*自二零一九年七月二十六日起獲委任*)

余昊先生

(*自二零一九年十一月十一日起獲委任*)

鄭學啟先生

(*自二零一九年五月九日起獲委任
並於二零一九年十一月一日辭任*)

洪海瀾女士

(*自二零一九年七月二十六日辭任*)

非執行董事

修遠先生

獨立非執行董事

朱依諄教授

(*自二零二零年十二月三十一日起獲委任*)

許麒麟先生

(*自二零二一年二月三日起獲委任*)

張瑞根先生

(*自二零二一年六月二十五日起獲委任*)

陳仲然先生

(*自二零一九年四月三日辭任*)

屠方魁先生

(*自二零二零年六月三十日辭任*)

王子豪先生

(*自二零二零年十一月二十四日辭任*)

隆軍先生

(*自二零二零年十一月三十日辭任*)

Company Information

公司資料

COMPANY SECRETARY

Ms. Li Yuen Shan

(appointed with effect from 9 April 2020)

Mr. Wong Yu Kit

(appointed with effect from 31 July 2019 and resigned with effect from 9 April 2020)

Mr. Zhou Chen

(appointed with effect from 11 January 2019 and resigned with effect from 31 July 2019)

Mr. Lock Kwong Hang, Simon

(resigned with effect from 11 January 2019)

AUTHORIZED REPRESENTATIVES

Mr. Chen Chengqing

Ms. Li Yuen Shan

(appointed with effect from 9 April 2020)

Mr. Wong Yu Kit

(appointed with effect from 31 July 2019 and resigned with effect from 9 April 2020)

Mr. Zhou Chen

(appointed with effect from 11 January 2019 and resigned with effect from 31 July 2019)

Mr. Lock Kwong Hang, Simon

(resigned with effect from 11 January 2019)

AUDIT COMMITTEE

Mr. Khor Khie Liem Alex (Chairman)

(appointed with effect from 3 February 2021)

Professor Zhu Yi Zhun

(appointed with effect from 31 December 2020)

Mr. Zhang Ruigen

(appointed with effect from 25 June 2021)

Mr. Tu Fangkui

(resigned with effect from 30 June 2020)

Mr. Wang Zihao (Chairman)

(resigned with effect from 24 November 2020)

Mr. Long Jun

(resigned with effect from 30 November 2020)

公司秘書

李婉珊女士

(自二零二零年四月九日起獲委任)

黃儒傑先生

(自二零一九年七月三十一日起獲委任並於二零二零年四月九日辭任)

周晨先生

(自二零一九年一月十一日起獲委任並於二零一九年七月三十一日辭任)

駱廣恒先生

(自二零一九年一月十一日辭任)

法定代表

陳成慶先生

李婉珊女士

(自二零二零年四月九日起獲委任)

黃儒傑先生

(自二零一九年七月三十一日起獲委任並於二零二零年四月九日辭任)

周晨先生

(自二零一九年一月十一日起獲委任並於二零一九年七月三十一日辭任)

駱廣恒先生

(自二零一九年一月十一日辭任)

審核委員會

許麒麟先生(主席)

(自二零二一年二月三日起獲委任)

朱依諄教授

(自二零二零年十二月三十一日起獲委任)

張瑞根先生

(自二零二一年六月二十五日起獲委任)

屠方魁先生

(自二零二零年六月三十日辭任)

王子豪先生(主席)

(自二零二零年十一月二十四日辭任)

隆軍先生

(自二零二零年十一月三十日辭任)

Company Information

公司資料

REMUNERATION COMMITTEE

- Mr. Khor Khie Liem Alex (*Chairman*)
(*appointed with effect from 3 February 2021*)
- Professor Zhu Yi Zhun
(*appointed with effect from 31 December 2020*)
- Mr. Zhang Ruigen
(*appointed with effect from 25 June 2021*)
- Mr. Chen Chengqing
Professor Zhang Rongqing
- Mr. Tu Fangkui
(*resigned with effect from 30 June 2020*)
- Mr. Wang Zihao (*Chairman*)
(*resigned with effect from 24 November 2020*)
- Mr. Long Jun
(*resigned with effect from 30 November 2020*)

NOMINATION COMMITTEE

- Mr. Chen Chengqing (*Chairman*)
Professor Zhu Yi Zhun
(*appointed with effect from 31 December 2020*)
- Mr. Khor Khie Liem Alex
(*appointed with effect from 3 February 2021*)
- Mr. Zhang Ruigen
(*appointed with effect from 25 June 2021*)
- Professor Zhang Rongqing
- Mr. Tu Fangkui
(*resigned with effect from 30 June 2020*)
- Mr. Wang Zihao
(*resigned with effect from 24 November 2020*)
- Mr. Long Jun
(*resigned with effect from 30 November 2020*)

AUDITOR

- ZHONGHUI ANDA CPA Limited
(*appointed with effect from 23 February 2021*)
- Crowe (HK) CPA Limited
(*resigned with effect from 23 February 2021*)
Certified Public Accountants

薪酬委員會

- 許麒麟先生 (*主席*)
(*自二零二一年二月三日起獲委任*)
- 朱依諄教授
(*自二零二零年十二月三十一日起獲委任*)
- 張瑞根先生
(*自二零二一年六月二十五日起獲委任*)
- 陳成慶先生
張榮慶教授
- 屠方魁先生
(*自二零二零年六月三十日辭任*)
- 王子豪先生 (*主席*)
(*自二零二零年十一月二十四日辭任*)
- 隆軍先生
(*自二零二零年十一月三十日辭任*)

提名委員會

- 陳成慶先生 (*主席*)
朱依諄教授
(*自二零二零年十二月三十一日起獲委任*)
- 許麒麟先生
(*自二零二一年二月三日起獲委任*)
- 張瑞根先生
(*自二零二一年六月二十五日起獲委任*)
- 張榮慶教授
- 屠方魁先生
(*自二零二零年六月三十日辭任*)
- 王子豪先生
(*自二零二零年十一月二十四日辭任*)
- 隆軍先生
(*自二零二零年十一月三十日辭任*)

核數師

- 中匯安達會計師事務所有限公司
(*自二零二一年二月二十三日起獲委任*)
- 國富浩華 (香港) 會計師事務所有限公司
(*自二零二一年二月二十三日起辭任*)
執業會計師

Company Information

公司資料

HONG KONG LEGAL ADVISOR

Raymond Siu & Lawyers
Units 1302–1303 & 1802
Ruttonjee House
11 Duddell Street
Central, Hong Kong

Michael Li & Co.
19/F., Prosperity Tower
39 Queen's Road Central
Central
Hong Kong

PRINCIPAL BANKER

Bank of China (Hong Kong) Limited
Bank of Communications Co., Ltd.
China Construction Bank
Industrial and Commercial Bank of China Limited

REGISTERED OFFICE

Grand Pavilion
Hibiscus Way
802 West Bay Road
P. O. Box 31119
KY1-1205
Cayman Islands

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 5, 7/F.
Nanyang Plaza
57 Hung To Road
Kwun Tong
Kowloon, Hong Kong

香港法律顧問

蕭鎮邦律師行
香港中環
都參利街11號
律敦治大廈
1302–1303及1802室

李智聰律師事務所
香港
中環
皇后大道中39號
豐盛創建大廈19樓

主要往來銀行

中國銀行(香港)有限公司
交通銀行股份有限公司
中國建設銀行
中國工商銀行股份有限公司

註冊辦事處

Grand Pavilion
Hibiscus Way
802 West Bay Road
P.O. Box 31119
KY1-1205
Cayman Islands

香港主要營業地點

香港九龍
觀塘
鴻圖道57號
南洋廣場
7樓5室

Company Information

公司資料

SHARE REGISTRARS AND TRANSFER OFFICES

Principal share registrar and transfer office

Royal Bank of Canada Trust Company
(Cayman) Limited
4th Floor, Royal Bank House
24 Shedden Road, George Town
Grand Cayman KY1-1110
Cayman Islands

*Hong Kong branch share registrar and
transfer office*

Computershare Hong Kong Investor Services
Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong

STOCK CODE

1889

WEBSITE

www.1889hk.com

股份過戶登記處

股份過戶登記總處

Royal Bank of Canada Trust Company
(Cayman) Limited
4th Floor, Royal Bank House
24 Shedden Road, George Town
Grand Cayman KY1-1110
Cayman Islands

股份過戶登記處香港分處

香港中央證券登記有限公司
香港灣仔
皇后大道東 183 號
合和中心
17 樓 1712-1716 號舖

股份代號

1889

網址

www.1889hk.com

Management Discussion and Analysis

管理層討論及分析

The board (the “Board”) of directors (the “Directors”) of Sanai Health Industry Group Company Limited (“Sanai Health Industry” or the “Company”) hereby presents the unaudited condensed consolidated financial statements of the Company and its subsidiaries (collectively referred to the “Group”) for the six-month ended 30 June 2020 (the “Current Period”) together with the comparative figures for the corresponding period in 2019.

BUSINESS REVIEW

During the six months ended 30 June 2020, the Group was principally engaged in four businesses: (i) pharmaceutical products business; (ii) finance leasing business; (iii) other general trading business; and (iv) genetic testing and molecular diagnostic services. The major business are stated as below:

Pharmaceutical Products Business

Since the acquisition of Fujian Yongchun Pharmaceutical Company Limited* (福建永春製藥有限公司) (“Fujian Yongchun”) and Fujian Zhixin Medicine Co., Limited* (福建至信醫藥有限公司) (“Fujian Zhixin”) in 2019, the Company continued to develop its core business, pharmaceutical products business.

三愛健康產業集團有限公司(「三愛健康產業」或「本公司»)董事(「董事»)會(「董事會»)謹此提呈本公司及其附屬公司(統稱「本集團»)截至二零二零年六月三十日止六個月(「本期間»)的未經審核簡明綜合財務報表，連同二零一九年同期的比較數字。

業務審視

截至二零二零年六月三十日止六個月，本集團主要從事四項業務：(i)醫藥產品業務；(ii)融資租賃業務；(iii)其他一般貿易業務；及(iv)基因檢測及分子生物診斷服務。主要業務載述如下：

醫藥產品業務

自二零一九年收購福建永春製藥有限公司(「福建永春»)及福建至信醫藥有限公司(「福建至信»)以來，本公司持續發展核心業務——醫藥產品業務。

Management Discussion and Analysis 管理層討論及分析

Fujian Yongchun is located in Yongchun County, Quanzhou City, Fujian Province. It occupies a site area of 32,330 square metres with a gross floor area of the plants of approximately 8,311.58 square metres, in which the GMP workshop has an area of 3,581 square metres. Fujian Yongchun owns 5 drug registration series (藥品批准文號) in the PRC and produces 5 types of oral medicine, including Yangpi San (養脾散), Sanqi panax notoginseng capsules (三七膠囊) and phentolamine mesylate tablets (甲磺酸酚妥拉明片). It becomes one of the important bases for pharmaceutical production of the Group.

The Group aims to increase its market share by further promoting core products and other products of Fujian Yongchun. To achieve this goal, the Group plans to adjust its current market position. In particular, the Group plans to enhance its sales and promotional strategies so as to strengthen its market penetration. The Group will continue to expand its sales team to further explore the traditional medicine market by introducing sales via drugstore chains and other channels. The Group will also fully leverage on its existing sales team to increase its sales through distributors.

福建永春位於福建省泉州市永春縣。其佔地面積為32,330平方米，廠房建築面積約8,311.58平方米，其中GMP車間佔3,581平方米。福建永春於中國擁有5個藥品批准文號和生產5種口服藥品，包括養脾散、三七膠囊及甲磺酸酚妥拉明片。福建永春成為本集團藥品生產的其中一個重要基地。

本集團旨在通過進一步推廣福建永春的核心產品和其他產品提升市場佔有率。為了實現這一目標，本集團計劃調整其當前市場定位。特別是，本集團計劃強化其銷售和促銷策略，增加市場滲透率。本集團將繼續擴張銷售團隊，通過連鎖藥店及其他渠道引入銷售以進一步發掘傳統醫藥市場。本集團還充分利用其現有銷售團隊通過經銷商提升其銷售額。

Management Discussion and Analysis

管理層討論及分析

Fujian Zhixin possesses the Medical Operations Permit (Wholesale), Medical Operation Quality Management System Certifications (GSP) and Food Operations Permit. The Group acts as a sales agent nationwide for the herbal medical materials, Chinese herbal medicine, Chinese patent medicine, chemical drug preparations, antibiotic preparations, biochemical pharmaceuticals, biological products, healthcare products and food products. Not only the Group can sell its pharmaceutical products through the sales network of Fujian Zhixin, but can also act as a sales agent to sell pharmaceuticals and healthcare products for other pharmaceutical companies.

During the Current Period, the revenue derived from pharmaceutical products business increased by approximately 560.70% to approximately RMB20.68 million (2019 interim: approximately RMB3.13 million).

Finance Leasing Business

Union Development Finance Lease (Shenzhen) Company Limited* (聯合發展融資租賃(深圳)有限公司), an indirect wholly-owned subsidiary of the Company, has been engaging in finance leasing business since 2017. The revenue derived from finance leasing business for the Current Period was approximately RMB3.30 million (2019 interim: RMB3.24 million).

Leveraging on the business platform, the Company will also develop leasing services of medical devices and rehabilitation equipment which is complimentary to the Group's existing pharmaceutical products business.

福建至信持有藥品經營的批發許可證、醫療營運質量管理系統證書(GSP)及食品經營許可證。本集團在全國範圍內代理銷售中藥材、中藥飲片、中成藥、化學藥製劑、抗生素製劑、生化藥品、生物製品、保健品及食品。本集團可以透過福建至信的銷售網絡銷售其醫藥產品，並作為代理銷售其他藥業公司的藥品和保健品。

於本期間，來自醫藥產品業務的收益增長約560.70%至約人民幣20.68百萬元(二零一九年中期：約人民幣3.13百萬元)。

融資租賃業務

本公司之間接全資附屬公司聯合發展融資租賃(深圳)有限公司，自二零一七年起一直從事融資租賃業務。於本期間，融資租賃業務所產生收益約為人民幣3.30百萬元(二零一九年中期：人民幣3.24百萬元)。

透過該商業平台，本公司亦會發展醫療器械及康復設備之租賃服務，以配合本集團之現有醫藥產品業務。

Management Discussion and Analysis

管理層討論及分析

Other General Trading Business

The Group operates other general trading business, including the trading of pharmaceutical related apparatus and products such as masks and oxygen machines, etc.. During the Current Period, other general trading business recorded a revenue of approximately RMB32.08 million (2019 interim: approximately RMB18.95 million), representing a significant increase of approximately 69.29%. The increase was mainly attributable to the trading of masks and oxygen machines which had high demand due to the outbreak of COVID-19 pandemic in 2020.

Genetic Testing and Molecular Diagnostic Services

The Group has acquired the equity interests in Zentrogene Bioscience Laboratory Limited ("Zentrogene") in April 2019 which primarily engages in the provision of services including genetic testing and molecular diagnostic services. Zentrogene operates a laboratory with the relevant license in Hong Kong, providing services comprising non-invasive prenatal diagnosis (NIPD), tumor genetic screening, DNA testing and paternity testing. Genetic testing is a prerequisite for precision medicine. During the Current Period, the revenue generated from genetic testing and molecular diagnostic services amounted to approximately RMB2.93 million (2019 interim: RMB1.37 million), representing an increase of 113.86%. The significant increase was due to the fact that the Group has only recorded three months of revenue of Zentrogene in the first six months' period in 2019 after completion of the acquisition of the same, and Zentrogene has established cooperative relationship with new business partners in Shenzhen which contributes to a growth in revenue in the Current Period.

其他一般貿易業務

本集團經營其他一般貿易業務，包括口罩和氧氣機等醫藥相關儀器及產品貿易。於本期間，其他一般貿易業務錄得收益約人民幣32.08百萬元(二零一九年中期：約人民幣18.95百萬元)，大幅增加約69.29%。增幅乃主要由於二零二零年COVID-19疫症爆發，口罩和氧氣機的需求偏高，導致貿易有所增加。

基因檢測及分子生物診斷服務

本集團已於二零一九年四月收購 Zentrogene Bioscience Laboratory Limited (「Zentrogene」) 的股權，該公司主要從事提供基因檢測及分子生物診斷服務。Zentrogene 在香港運營一家持有相關執照的化驗所，提供唐氏篩查(NIPD)、腫瘤基因篩查、遺傳基因檢測及親子鑒定服務。基因檢測是精準醫療的必要前提。於本期間，基因檢測及分子生物診斷服務所得收益約為人民幣2.93百萬元(二零一九年中期：人民幣1.37百萬元)，增加113.86%。大幅增長乃由於本集團於完成上述收購後於二零一九年首六個月僅錄得 Zentrogene 的三個月收益，而 Zentrogene 已於深圳與新業務夥伴建立合作關係，促使收益於本期間有所增長。

Management Discussion and Analysis

管理層討論及分析

FINANCIAL REVIEW

For the six months ended 30 June 2020, the Group has a total revenue of approximately RMB59.00 million from its continuing operations, representing an increase of approximately 121.31% as compared to approximately RMB26.66 million in the corresponding period for 2019, and the gross profit margin from the continuing operation was approximately 19.84% (2019 interim: gross profit margin approximately 10.95%). The Group recorded a profit attributable to owners of the Company of approximately RMB2.42 million (2019 interim: approximately RMB146.73 million). Profit attributable to owners of the Company for the Current Period dropped significantly as compared to the corresponding period in 2019 was due to the fact that the profit for the corresponding period in 2019 was mainly generated from the one-off gain on disposal of subsidiaries which amounted to approximately RMB111.99 million. The basic and diluted earnings per share was approximately RMB0.1 cents (2019 interim: basic and diluted earnings per share was approximately RMB4.7 cents).

Liquidity, Financial Resources and Capital Structure

As at 30 June 2020, the Group had cash and cash equivalents of approximately RMB6.76 million (as at 31 December 2019: approximately RMB4.20 million) and most cash and cash equivalents were denominated in Renminbi and Hong Kong dollars.

財務回顧

截至二零二零年六月三十日止六個月，本集團持續經營業務之總收益約為人民幣59.00百萬元，較二零一九年同期約人民幣26.66百萬元增加約121.31%，持續經營業務之毛利率約為19.84%（二零一九年中期：毛利率約10.95%）。本集團錄得本公司擁有人應佔溢利約人民幣2.42百萬元（二零一九年中期：約人民幣146.73百萬元）。於本期間，本公司擁有人應佔溢利較二零一九年同期大幅下降，乃由於二零一九年同期之溢利乃主要來自出售附屬公司的單次收益約人民幣111.99百萬元。每股基本及攤薄盈利約為人民幣0.1分（二零一九年中期：每股基本及攤薄盈利約為人民幣4.7分）。

流動資金、財政資源及資本結構

於二零二零年六月三十日，本集團之現金及現金等價物約為人民幣6.76百萬元（於二零一九年十二月三十一日：約人民幣4.20百萬元），而大部分現金及現金等價物以人民幣及港元計值。

Management Discussion and Analysis

管理層討論及分析

The Group had reviewed the capital structure by using gearing ratio. The gearing ratio represents the total debt, which includes trade and other payables of the Group, divided by total equity of the Group. The gearing ratio of the Group was approximately 42.55% as at 30 June 2020 (as at 31 December 2019: approximately 33.18%).

Exposure to Fluctuation in Exchange Rates

During the six months ended 30 June 2020, the Group conducted most of its business transactions in Renminbi. The Group had not experienced any material difficulties or negative impacts on its operations as a result of fluctuations in currency exchange rates. As at 30 June 2020, the Group did not have any foreign exchange contracts, interest or currency swaps or other financial derivatives for hedging purpose. Therefore, the Group was not exposed to any material interest and exchange risks during the Current Period. The management, however, will monitor and consider hedging foreign currency exposure should the need arise.

本集團運用資產負債比率檢討資本結構。資產負債比率指本集團之總負債(包括貿易應付款項及其他應付款項)除以本集團之總權益。本集團於二零二零年六月三十日之資產負債比率約為42.55%(於二零一九年十二月三十一日:約33.18%)。

匯率波動風險

於截至二零二零年六月三十日止六個月，本集團大部分業務交易以人民幣進行。本集團從未因貨幣匯率波動而遭遇重大困難，且其營運亦未因此承受負面影響。於二零二零年六月三十日，本集團並無任何外匯合約、利息或貨幣掉期或其他用作對沖的金融衍生工具。因此，本集團於本期間並無任何重大利率及匯兌風險。然而，管理層將監察並考慮在需要時對沖外匯風險。

Management Discussion and Analysis

管理層討論及分析

THE STOCK EXCHANGE'S NOTICE TO SUSPEND TRADING IN THE COMPANY'S SHARES

The Company received a letter dated 24 May 2019 from the Stock Exchange of Hong Kong Limited (the "Stock Exchange"), which served a notice that the Stock Exchange considered that the Company has failed to maintain a sufficient level of operations or have tangible assets of sufficient value and/or intangible assets for which a sufficient potential value could be demonstrated under Rule 13.24 of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") to warrant the continued listing of the shares of the Company (the "Shares"). The Stock Exchange has therefore decided to suspend trading in the Shares under Rule 6.01(3) of the Listing Rules and proceed with cancellation of the listing of the Company under 6.01A(1) of the Listing Rules (the "Decision").

The Company was required to re-comply with Rule 13.24 of the Listing Rules and would have a remedial period of 18 months to re-comply with the Listing Rules. If the Company failed to do so by the expiry of the 18-month period (i.e. on or before 23 November 2020), the Stock Exchange would proceed with cancellation of the listing of the Company.

After seeking professional advice, on 4 June 2019, the Company had submitted a written request to the listing committee (the "Listing Committee") of the Stock Exchange for the Decision to be referred to the Listing Committee for review pursuant to Rule 2B.06(1) of the Listing Rules.

聯交所通知暫停買賣本公司股份

本公司已收到香港聯合交易所有限公司（「聯交所」）於二零一九年五月二十四日發出的函件，當中載述聯交所認為本公司未能維持足夠的營運水平或擁有足夠價值的有形資產及／或根據聯交所證券上市規則（「上市規則」）第13.24條所指足夠潛在價值的無形資產以保證本公司股份（「股份」）繼續上市。因此，聯交所決定根據上市規則第6.01(3)條暫停買賣股份，並根據上市規則第6.01A(1)條將本公司除牌（「該決定」）。

本公司須重新遵守上市規則第13.24條，並將可於18個月糾正期間重新遵守上市規則。倘本公司未能於18個月期間屆滿（即二零二零年十一月二十三日或之前）前達成上述要求，則聯交所將對本公司進行除牌。

尋求專業意見後，本公司於二零一九年六月四日根據上市規則第2B.06(1)條向聯交所上市委員會（「上市委員會」）提出書面申請，要求將該決定提交上市委員會覆核。

Management Discussion and Analysis

管理層討論及分析

The Board emphasized that the Group was undergoing a period of transformation. The Group has terminated its business with continued losses and disposed of its assets with substantial net liabilities for the interests of the Company and shareholders as a whole. The Board will use its best efforts to improve the Group's overall performance in the future.

On 6 September 2019, the Company has received a letter from the Listing Committee setting out its decision on the review application (the "Decision Letter"). According to the Decision Letter, the Listing Committee decided to uphold the Decision to suspend trading in the Shares. The trading in the shares was suspended and the Company would be required to resume trading within a period of 18 months from the date of the suspension. If the Company failed to do so, the Stock Exchange would proceed with cancellation of the listing of the Company.

After seeking professional advice, the Company submitted a written request to the Listing (Review) Committee ("Listing (Review) Committee") of the Stock Exchange for the Decision to be referred to the Listing (Review) Committee for review (the "2nd Review Request") pursuant to Rule 2B.06(2) of the Listing Rules.

On 23 January 2020, the Company had received a reply from the Listing (Review) Committee that they had decided to uphold the decision of the Listing Committee. The Company was required to re-comply with Rule 13.24 of the Listing Rules and resume trading within a period of 18 months. If the Company failed to do so by the expiry of the 18-month period, the Stock Exchange would proceed with cancellation of the Company's listing.

董事會強調本集團正處於轉型期。為維護本公司及股東的整體利益，本集團已終止經營持續虧損的舊業務，並已出售錄得重大負債淨額的資產。董事會日後將竭力改善本集團的整體表現。

於二零一九年九月六日，本公司接獲上市委員會函件，當中載列有關覆核申請之決定（「決定函件」）。根據決定函件，上市委員會決定維持暫停股份交易的決定。股份暫停交易且本公司須於暫停日期起計18個月期間內恢復交易。倘本公司未能如此行事，聯交所將對本公司進行除牌。

在尋求專業意見後，本公司已根據上市規則第2B.06(2)條向聯交所上市（覆核）委員會（「上市（覆核）委員會」）提交有關將該決定轉交上市（覆核）委員會覆核的書面要求（「第二次覆核要求」）。

於二零二零年一月二十三日，本公司接獲上市（覆核）委員會的回覆，表示彼等決定維持上市委員會的決定。本公司須重新遵守上市規則第13.24條，並於18個月期間內恢復股份買賣。倘本公司未能於18個月期間屆滿前如此行事，聯交所將對本公司進行除牌。

Management Discussion and Analysis

管理層討論及分析

By way of letters to the Company dated 12 February 2020, 7 April 2020 and 18 January 2021, the Stock Exchange imposed the following resumption guidance for the Company:

- (i) Demonstrate its compliance with Rule 13.24 of the Listing Rules;
- (ii) Publish all outstanding financial results and address any audit modifications; and
- (iii) Re-comply with Rules 3.10, 3.10A, 3.21 and 3.25 of the Listing Rules.

For further details, please refer to the announcements of the Company dated 26 May 2019, 28 May 2019, 4 June 2019, 9 September 2019, 16 September 2019, 24 January 2020, 12 February 2020, 7 April 2020, 23 April 2020, 24 July 2020, 23 October 2020, 18 January 2021, 22 April 2021 and 12 July 2021 respectively.

SIGNIFICANT INVESTMENTS, ACQUISITIONS AND DISPOSALS

During the Current Period, there was no significant investment held or material acquisition or disposals of subsidiaries, associates and joint venture by the Group.

通過日期為二零二零年二月十二日、二零二零年四月七日及二零二一年一月十八日的致本公司函件，聯交所對本公司發出以下復牌指引：

- (i) 證明其遵守上市規則第13.24條；
- (ii) 發佈所有待刊發的財務業績，並處理任何審計修訂；及
- (iii) 重新遵守上市規則第3.10、3.10A、3.21及3.25條。

更多詳情請參閱本公司日期分別為二零一九年五月二十六日、二零一九年五月二十八日、二零一九年六月四日、二零一九年九月九日、二零一九年九月十六日、二零二零年一月二十四日、二零二零年二月十二日、二零二零年四月七日、二零二零年四月二十三日、二零二零年七月二十四日、二零二零年十月二十三日、二零二一年一月十八日、二零二一年四月二十二日及二零二一年七月十二日的公告。

重要投資、收購及出售

於本期間，本集團概無持有重大投資或重大收購或出售附屬公司、聯營公司及合營公司。

Management Discussion and Analysis

管理層討論及分析

EMPLOYEES

For the six months ended 30 June 2020, the Group employed approximately 69 employees (2019 interim: 74 employees) with total staff cost of approximately RMB4.04 million (2019 interim: approximately RMB3.0 million). The Group determined staff remuneration in accordance with the prevailing market salary scales, individual qualifications and performance. Remuneration packages including performance bonuses and entitlements to share options are reviewed on a regular basis.

CAPITAL EXPENDITURE

For the six months ended 30 June 2020 and 30 June 2019, there was no significant capital expenditure of the Group for property, plant and equipment.

CAPITAL COMMITMENTS, CONTINGENT LIABILITIES AND CHARGES ON ASSETS

As at 30 June 2020, the Group did not have any significant capital commitment (2019: nil).

Save as disclosed in this report, the Group did not have any other significant contingent liabilities as at 30 June 2020.

As at 30 June 2020, there was no land use rights and property, plant and equipment which had been pledged as security for the borrowings of the Group (2019: nil).

僱員

於截至二零二零年六月三十日止六個月，本集團聘用約69名僱員（二零一九年中期：74名僱員），總員工成本約為人民幣4.04百萬元（二零一九年中期：約人民幣3.0百萬元）。本集團按當前市場薪酬水平、個人資歷及表現釐定員工薪酬。薪酬待遇包括表現花紅及獲發購股權之權利，並作定期檢討。

資本開支

於截至二零二零年六月三十日及二零一九年六月三十日止六個月，本集團並無物業、廠房及設備的重大資本開支。

資本承擔、或然負債及資產抵押

於二零二零年六月三十日，本集團並無任何重大資本承擔（二零一九年：無）。

除本報告所披露者外，本集團於二零二零年六月三十日並無任何其他重大或然負債。

於二零二零年六月三十日，概無土地使用權以及物業、廠房及設備抵押為本集團借貸的抵押品（二零一九年：無）。

Other Information 其他資料

DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2020 (2019 interim: Nil).

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to the Listing Rules as the Company's own code for securities transactions by its Directors. In addition, the Company has made specific enquiries with all Directors and all Directors confirmed that during the six months ended 30 June 2020, they had fully complied with the required standards as set out in the Model Code.

SHARE OPTION SCHEME

On 24 May 2018 and 30 May 2018, 115,400,000 and 118,000,000 share options (the "Share Options") under the share option scheme of the Company adopted on 16 June 2017 (the "Share Option Scheme") were granted to grantees respectively. On 7 June, 8 June, 14 June and 19 June 2018, an aggregate of 195,100,000 Share Options were exercised by the grantees. The following table sets out movements in the Share Options during the Current Period:

股息

董事會並不建議就截至二零二零年六月三十日止六個月派發中期股息(二零一九年中期：無)。

董事進行證券交易

本公司已採納上市規則附錄十所載上市發行人董事進行證券交易的標準守則(「標準守則」)，作為本公司董事進行證券交易之守則。此外，本公司已向全體董事作出具體查詢，全體董事確認於截至二零二零年六月三十日止六個月內，彼等已全面遵守標準守則所載的規定標準。

購股權計劃

於二零一八年五月二十四日及二零一八年五月三十日，根據本公司於二零一七年六月十六日採納之購股權計劃(「購股權計劃」)，115,400,000份及118,000,000份購股權(「購股權」)已分別授予承授人。於二零一八年六月七日、六月八日、六月十四日及六月十九日，承授人已行使合共195,100,000份購股權。下表載列於本期間購股權之變動：

Other Information 其他資料

Number of share options 購股權數目									
Category of participant 參與人士類別	At 1 January 2020	Granted during the period 期內授出	Cancelled or lapsed during the period 期內註銷 或失效	Exercised during the period 期內行使	At 30 June 2020	Date of grant 授出日期	Exercise period 行使期	Exercise price 行使價	Closing price of the shares immediately before the date of grant 緊接 授出日期前 股份收市價
	於二零二零年 一月一日 (HK\$) (港元)				於二零二零年 六月三十日 (HK\$) (港元)				
Employees in aggregate 僱員總數	34,800,000	-	-	-	34,800,000	24 May 2018 and 30 May 2018 二零一八年 五月二十四日 及二零一八年 五月三十日	24 May 2018 to 29 May 2023 (Note) 二零一八年 五月二十四日 至二零二三年 五月二十九日 (附註)	-	-
Non-employees in aggregate 非僱員總數	2,000,000	-	-	-	2,000,000	30 May 2018 二零一八年 五月三十日	30 May 2018 to 29 May 2023 (Note) 二零一八年 五月三十日 至二零二三年 五月二十九日 (附註)	-	-
	36,800,000	-	-	-	36,800,000				

Note: The Share Options are not subject to any vesting period.

附註：購股權並不受任何歸屬期所限。

Other Information 其他資料

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2020, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) ("SFO")) as recorded in the register maintained by the Company pursuant to section 352 of the SFO or otherwise notified to the Company and the Stock Exchange pursuant to the Model Code as set out in Appendix 10 to the Listing Rules, were as follows:

董事及最高行政人員於本公司及其相聯法團股份、相關股份及債權證的權益及淡倉

於二零二零年六月三十日，董事及最高行政人員於本公司或其任何相聯法團（香港法例第571章證券及期貨條例（「證券及期貨條例」）第XV部所界定）的股份、相關股份或債權證中，擁有根據證券及期貨條例第352條須列入本公司所存置登記冊，或根據上市規則附錄十所載標準守則規定須知會本公司及聯交所之權益或淡倉如下：

Name of Directors 董事姓名	Company/name of associated corporation 公司／相聯法團名稱	Capacity 身份	Number of shares (Note 1) 股份數目 (附註1)	Approximate percentage of interest 概約權益 百分比
Mr. Chen Chengqing ("Mr. Chen") 陳成慶先生（「陳先生」）	The Company 本公司	Interest in controlled corporation (Note 2) 受控法團權益(附註2)	836,735,000 (L)	27.28%
		Beneficial owner (Note 2) 實益擁有人(附註2)	2,800,000 (L)	0.09%
Professor Zhang Rongqing 張榮慶教授	The Company 本公司	Beneficial Owner 實益擁有人	22,000,000 (L)	0.72%

Notes:

1. The letter "L" denotes long position in the shares.
2. According to the disclosure of interest form submitted by Mr. Chen on 30 May 2018 in accordance with Part XV of the SFO, 836,753,000 of these shares are registered in the name of Cyber Success Global Investments Limited ("Cyber Success"), which is wholly owned by Mr. Chen. By virtue of the SFO, Mr. Chen is deemed to be interested in all the shares in which Cyber Success is interested. Mr. Chen is also beneficially interested in 2,800,000 shares of the Company.
3. The percentage of shareholding is calculated on the basis of 3,067,222,500 issued shares of the Company as at the date of this report.

Save as disclosed above, none of the Directors or chief executive of the Company is aware of any other Director or chief executive of the Company who has any interests or short positions in any shares, underlying shares and debentures of the Company or any of its associated corporation which were required to be recorded in the register maintained by the Company pursuant to section 352 of the SFO or otherwise notified to the Company and the Stock Exchange pursuant to the Model Code as at 30 June 2020.

附註：

1. 「L」指於股份中之好倉。
2. 根據由陳先生於二零一八年五月三十日提交的證券及期貨條例第XV部披露權益表格，該等股份中之836,753,000股以陳先生全資擁有的Cyber Success Global Investments Limited（「Cyber Success」）之名義登記。根據證券及期貨條例，陳先生被視為於Cyber Success擁有權益之全部股份中擁有權益。陳先生亦於本公司2,800,000股股份中擁有實際權益。
3. 股權百分比按本報告日期之本公司已發行股份3,067,222,500股作基準計算。

除上文所披露者外，於二零二零年六月三十日，就本公司董事或最高行政人員所知，任何本公司其他董事或最高行政人員並無於本公司或任何相聯法團的任何股份、相關股份以及債權證中擁有根據證券及期貨條例第352條須列入本公司所存置登記冊或根據標準守則須知會本公司及聯交所之任何權益或淡倉。

Other Information 其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES IN THE COMPANY

As at 30 June 2020, the following persons, other than a director or chief executive of the Company, had an interest or a short position in the shares or underlying shares in the Company as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO:

主要股東於本公司之股份及相關股份的權益及淡倉

於二零二零年六月三十日，以下人士（本公司董事或最高行政人員除外）於本公司股份或相關股份擁有根據證券及期貨條例第336條須列入本公司所存置登記冊的權益或淡倉如下：

Name of shareholder 股東名稱／姓名	Capacity 身份	Number of shares (Note 1) 股份數目 (附註1)	Approximate percentage of shareholding (Note 2) 概約股權 百分比 (附註2)
Mr. Chen Chengqing ("Mr. Chen") 陳成慶先生（「陳先生」）	Interest in controlled corporation (Note 2) 受控法團權益(附註2)	836,753,000 (L)	27.28%
	Beneficial owner (Note 2) 實益擁有人(附註2)	2,800,000 (L)	0.09%
Cyber Success	Beneficial owner (Note 2) 實益擁有人(附註2)	836,753,000 (L)	27.28%

Notes:

- (1) The letter "L" denotes long position in the shares of the Company.
- (2) According to the disclosure of interest form submitted by Mr. Chen on 30 May 2018 in accordance with Part XV of the SFO, 836,753,000 of these shares are registered in the name of Cyber Success, which is wholly owned by Mr. Chen. By virtue of the SFO, Mr. Chen is deemed to be interested in all the shares in which Cyber Success is interested. Mr. Chen is also beneficially interested in 2,800,000 shares of the Company.

附註：

- (1) (L)指於本公司股份中之好倉。
- (2) 根據由陳先生於二零一八年五月三十日提交的證券及期貨條例第XV部披露權益表格，該等股份中之836,753,000股以陳先生全資擁有的Cyber Success之名義登記。根據證券及期貨條例，陳先生被視為於Cyber Success擁有權益之全部股份中擁有權益。陳先生亦於本公司2,800,000股股份中擁有實際權益。

Other Information 其他資料

(3) The percentage of shareholding is calculated on the basis of 3,067,222,500 issued shares of the Company as at 30 June 2020.

Save as disclosed above, the Company was not aware of any person, other than the Directors of the Company whose interests or short positions are set out in the paragraph headed “Directors’ and chief executive’s interests and short positions in shares, underlying shares and debentures of the Company and its associated corporations” above, who had an interest or a short position in the shares or underlying shares in the Company which were required to be recorded in the register to be kept by the Company under section 336 of the SFO as at 30 June 2020.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the listed securities of the Company during the Current Period.

CHANGE OF DIRECTORS’ INFORMATION

Pursuant to Rule 13.51B of the Listing Rules, the changes of information of the Directors since the date of the Company’s 2019 Annual Report are set out below:

With effect from 30 June 2020, Mr. Tu Fangkui resigned as an independent non-executive Director and ceased to be a member of each of the audit committee, the remuneration committee and the nomination committee, due to his intention to pursue other business opportunities. Further details were disclosed in the Company’s announcement dated 30 June 2020.

(3) 股權百分比按二零二零年六月三十日本公司已發行股份3,067,222,500股作基準計算。

除上文所披露者外，於二零二零年六月三十日，本公司並無知悉任何人士（其權益或淡倉載於上文「董事及最高行政人員於本公司及其相聯法團股份、相關股份及債權證的權益及淡倉」一段的董事除外）於本公司股份或相關股份擁有根據證券及期貨條例第336條須列入本公司所存置登記冊的權益或淡倉。

購買、出售或贖回本公司上市證券

截至本期間，本公司或其任何附屬公司概無購買、出售或贖回本公司的任何上市證券。

董事資料變動

根據上市規則第13.51B條，自本公司二零一九年年報日期以來的董事資料變動如下：

屠方魁先生因其有意另謀其他業務機遇而辭任獨立非執行董事，並不再擔任審核委員會、薪酬委員會及提名委員會各自的成員，自二零二零年六月三十日起生效。有關進一步詳情已於本公司日期為二零二零年六月三十日的公告中披露。

Other Information 其他資料

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company is committed to achieving a high standard of corporate governance practice, such that the interests of the Company's shareholders, customers, employees as well as the long-term development of the Company can be safeguarded.

The Company has complied with the provisions as set out in the Corporate Governance Code ("CG Code") in Appendix 14 to the Listing Rules during the six months ended 30 June 2020, except for deviation from code provision A.2.1 and A.5.1 of the CG Code. The Company also failed to comply with Rules 3.10, 3.10A, 3.21 and 3.25 of the Listing Rules.

In respect of the code provision A.2.1 of the CG Code, the roles of chairman (the "Chairman") and chief executive officer ("CEO") of the Company shall be separated and shall not be performed by the same individual. The Board considered that vesting the roles of Chairman and the CEO in the same person facilitates the execution of the Company's business strategies and maximizes effectiveness of its operations. On the other hand, there are three independent non-executive Directors on the Board, all of them are independent from the Company and the Board believes that there is a sufficient check and balance on the Board. Therefore the Board considers the Company has provided sufficient protection to its interests and the interests of its shareholders. The Board shall review the structure from time to time and shall consider the appropriate adjustment should circumstances require.

遵守企業管治守則

本公司致力達至高度的企業管治常規，以保障本公司股東、客戶及員工利益以及本公司長遠發展。

除偏離《企業管治守則》（「企業管治守則」）守則條文第A.2.1條及第A.5.1條外，於截至二零二零年六月三十日止六個月，本公司已遵守上市規則附錄十四企業管治守則所載條文。本公司亦未能遵守上市規則第3.10、3.10A、3.21及3.25條。

根據企業管治守則守則條文第A.2.1條，本公司主席（「主席」）與行政總裁（「行政總裁」）的角色應有所區分，並不應由一人同時兼任。董事會認為，由同一人士擔任主席及行政總裁職位，有助本公司執行業務策略，盡量提升其業務運作的效率。另一方面，董事會有三名獨立非執行董事，彼等均獨立於本公司，董事會相信董事會中存在足夠制衡，故董事會認為本公司已就其權益及其股東權益提供足夠保障。董事會將不時檢討有關架構，並於需要時考慮適當調整。

Following the resignation of Mr. Tu Fangkui as an independent non-executive Director, member of the Audit Committee, member of the remuneration Committee and member of the Nomination Committee of the Company on 30 June 2020, the Company only had two independent non-executive Directors, namely Mr. Wang Zihao (“Mr. Wang”) and Mr. Long Jun (“Mr. Long”), and failed to meet the requirements of having: (a) at least three independent non-executive directors on the Board under Rule 3.10(1) of the Listing Rules; (b) independent non-executive directors who represent at least one-third of the Board under Rule 3.10A of the Listing Rules; (c) the Audit Committee comprising only non-executive directors with a minimum of three members under Rule 3.21 of the Listing Rules; (d) the Remuneration Committee comprising a majority of independent non-executive directors under Rule 3.25 of the Listing Rules; and (e) the Nomination Committee comprising a majority of independent non-executive directors under code provision A.5.1 of the CG Code in Appendix 14 to the Listing Rules.

AUDIT COMMITTEE

An audit committee has been established by the Company to review the financial reporting process, risk management and internal control systems of the Group. As at the date of this report, the audit committee of the Company comprises three independent non-executive Directors, namely Mr. Khor Khie Liem Alex, Prof. Zhu Yi Zhun and Mr. Zhang Ruigen. Mr. Khor Khie Liem Alex serves as the chairman of the audit committee of the Company, who has the professional qualification and experience in financial matters in compliance with the requirements of the Listing Rules.

繼屠方魁先生於二零二零年六月三十日辭任本公司獨立非執行董事、審核委員會成員、薪酬委員會成員及提名委員會成員後，本公司僅有兩名獨立非執行董事（即王子豪先生（「王先生」）及隆軍先生（「隆先生」）），因此未能滿足下列規定：(a) 根據上市規則第3.10(1)條，董事會必須包括至少三名獨立非執行董事；(b) 根據上市規則第3.10A條，獨立非執行董事必須佔董事會成員人數至少三分之一；(c) 根據上市規則第3.21條，審核委員會僅由具備至少三名成員之非執行董事組成；(d) 根據上市規則第3.25條，薪酬委員會大部分成員須為獨立非執行董事；及(e) 根據上市規則附錄十四企業管治守則之守則條文第A.5.1條，提名委員會須由大多數獨立非執行董事組成。

審核委員會

本公司成立審核委員會，以審閱本集團的財務申報程序、風險管理及內部監控系統。於本報告日期，本公司審核委員會由三名獨立非執行董事組成，即許麒麟先生、朱依諄教授及張瑞根先生。許麒麟先生為本公司審核委員會主席，彼已遵守上市規則規定具備於財務事宜方面的專業資格及經驗。

Other Information 其他資料

The audit committee has reviewed with the management the accounting principles and practices adopted by the Group and discussed internal control and financial reporting matters including the review of the unaudited condensed consolidated interim financial statements of the Group for the Current Period. They considered that the unaudited interim financial statements of the Group for the Current Period are in compliance with the relevant accounting standards, rules and regulations and that appropriate disclosures have been made.

REMUNERATION COMMITTEE

As at the date of this report, the remuneration committee of the Company comprises three independent non-executive Directors and two executive Directors, and is responsible for assisting the Board to oversee the Company's remuneration packages, bonus and other compensation payable to Directors and senior management and establishing a formal and transparent procedure for developing policy on such remuneration.

NOMINATION COMMITTEE

As at the date of this report, the nomination committee (the "Nomination Committee") of the Company comprises three independent non-executive Directors and two executive Directors, and is responsible for reviewing the structure, size and composition of the Board, identifying individuals who are suitably qualified to become a member of the Board, and assessing the independence of the independent non-executive Directors. Having regard to the independence and quality of nominees, the Nomination Committee shall make recommendations to the Board so as to ensure that all nominations are fair and transparent. The Nomination Committee is also responsible for reviewing the succession plan for Directors, in particular the chairman and the chief executive.

審核委員會已與管理層審閱本集團採納的會計原則及常規，並討論內部監控及財務申報事宜，包括審閱本集團於本期間的未經審核簡明綜合中期財務報表。彼等認為本集團於本期間的未經審核中期財務報表符合相關會計準則、規則及規例，並已作出適當披露。

薪酬委員會

於本報告日期，本公司的薪酬委員會由三名獨立非執行董事及兩名執行董事組成，負責協助董事會監督本公司的薪酬待遇、花紅及其他應付予董事及高級管理層的補償，並為制訂該等薪酬政策而設立正式且具透明度的程序。

提名委員會

於本報告日期，本公司的提名委員會（「提名委員會」）由三名獨立非執行董事及兩名執行董事組成，負責檢討董事會的架構、人數及組成部分、物色具適合資格出任董事會成員的人選及評估獨立非執行董事的獨立性。經考慮被提名人士的獨立性及品格後，提名委員會須向董事會提供推薦意見，以確保所有提名均為公平及透明。提名委員會亦負責審閱董事繼任計劃，尤其是主席及行政總裁。

PUBLICATION OF INTERIM REPORT

The 2020 interim report containing all the information required by the Listing Rules will be despatched to shareholders as well as made available on our Company's website at www.1889hk.com and the Stock Exchange's website at www.hkexnews.hk respectively in due course.

ACKNOWLEDGEMENT

I would like to express the Board's sincere gratitude to the management team and all other employees for their hard work and dedication. Their excellence and commitment are of vital importance in enhancing the sustainability of the Group. Finally, I would like to take this opportunity to thank our shareholders and all other stakeholders for their continuous support and confidence in us.

On behalf of the Board
CHEN CHENGQING
Chairman

Hong Kong, 16 July 2021

刊發中期報告

二零二零年中期報告(載有上市規則所規定的所有資料)將適時寄發予股東，並將分別載於本公司網站www.1889hk.com及聯交所網站www.hkexnews.hk以供閱覽。

致謝

本人謹代表董事會，對管理層團隊及所有其他僱員的努力及熱誠，致以衷心感謝。彼等的卓越表現及承擔對提高本集團的持續發展起著關鍵作用。最後，本人藉此機會感謝各股東及其他利益相關者一直以來的鼎力支持及信任。

代表董事會
主席
陳成慶

香港，二零二一年七月十六日

Condensed Consolidated Statement of Profit or Loss

簡明綜合損益表

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

	Notes 附註	2020 2020年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2019 2019年 RMB'000 人民幣千元 (Unaudited) (未經審核) (Restated) (經重列)
Continuing operations			
Revenue			
Cost of sales and services rendered	5	58,995 (47,292)	26,662 (23,742)
Gross profit		11,703	2,920
Other income and other gain, net		787	7,011
Distribution costs		(892)	(61)
Administrative and other expenses		(6,568)	(10,777)
Finance costs	6(a)	-	(27)
Profit/(loss) before income tax		5,030	(934)
Income tax expenses	9	(1,573)	(259)
Profit/(loss) for the period from continuing operations		3,457	(1,193)
Discontinued operation			
Profit for the year from discontinued operation	8	-	147,930
Profit for the period	6(b)	3,457	146,737
Attributable to:			
Owners of the Company			
— Profit/(loss) from continuing operations		2,417	(1,200)
— Profit from discontinued operation		-	147,930
Profit attributable to owners of the Company		2,417	146,730

Condensed Consolidated Statement of Profit or Loss (Continued)

簡明綜合損益表(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

		2020	2019
	Notes	2020年	2019年
	附註	RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
Non-controlling interests	非控股權益		
— Profit from continuing operations	— 持續經營業務溢利	1,040	7
Profit/(loss) attributable to non-controlling interests	非控股權益應佔溢利/(虧損)	1,040	7
		3,457	146,737
Earnings/(loss) per share	每股盈利/(虧損)		
Basic and diluted (RMB cents)	基本及攤薄(人民幣分)		
— from continuing and discontinued operations	— 持續經營及已終止業務	0.1	4.7
— from continuing operations	— 持續經營業務	0.1	(0.1)
— from discontinued operation	— 已終止業務	-	4.8

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

簡明綜合損益及其他全面收益表

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
			(Restated)
			(經重列)
Profit for the period	期內溢利	3,457	146,737
Other comprehensive loss:	其他全面虧損：		
<i>Items that may be reclassified subsequently to profit or loss:</i>	其後或會重新分類至損益之項目：		
Exchange differences on translation of foreign operations	換算海外業務之匯兌差額	(585)	(242)
Total comprehensive income for the period	期內全面收益總額	2,872	146,495
Attributable to:	以下人士應佔：		
— Owners of the Company	— 本公司擁有人	1,832	146,488
— Non-controlling interests	— 非控股權益	1,040	7
		2,872	146,495

Condensed Consolidated Statement of Financial Position

簡明綜合財務狀況表

At 30 June 2020

於二零二零年六月三十日

		30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
NON-CURRENT ASSETS			
Property, plant and equipment	物業、廠房及設備	10,926	10,750
Right-of-use assets	使用權資產	4,595	4,660
Deposits for acquisition of non-current assets	收購非流動資產之訂金	-	23,705
Intangible assets	無形資產	37,839	38,824
Deferred tax assets	遞延稅項資產	521	1,555
Finance lease receivables	融資租賃應收款項	-	98,095
		53,881	177,589
CURRENT ASSETS			
Inventories	存貨	5,235	4,329
Trade and other receivables	貿易應收款項及其他應收款項	111,147	66,589
Tax recoverable	可收回稅項	31	17
Finance lease receivables	融資租賃應收款項	98,095	-
Financial assets at fair value through profit or loss	按公平值計入損益之金融資產	662	651
Cash and cash equivalents	現金及現金等價物	6,759	4,195
		221,929	75,781
CURRENT LIABILITIES			
Trade and other payables	貿易應付款項及其他應付款項	81,029	62,249
Tax payables	應付稅項	2,017	984
		83,046	63,233

Condensed Consolidated Statement of Financial Position (Continued)

簡明綜合財務狀況表(續)

At 30 June 2020

於二零二零年六月三十日

		30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
NET CURRENT ASSETS	淨流動資產	138,883	12,548
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債	192,764	190,137
NON-CURRENT LIABILITIES	非流動負債		
Deferred tax liabilities	遞延稅項負債	2,326	2,571
NET ASSETS	淨資產	190,438	187,566
CAPITAL AND RESERVES	資本及儲備		
Share capital	股本	28,601	28,601
Reserves	儲備	153,237	151,405
Equity attributable to owners of the Company	本公司擁有人應佔權益	181,838	180,006
Non-controlling interests	非控股權益	8,600	7,560
TOTAL EQUITY	總權益	190,438	187,566

Consolidated Statement of Changes in Equity

簡明綜合權益變動表

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

		Attributable to owners of the Company 本公司擁有人應佔											
		Share capital	Share premium	Share option reserve	Special reserve	Capital reserve	Statutory surplus reserve	Translation reserve	Non-distributable reserve	Accumulated losses	Sub-total	Non-controlling interests	Total
		股本	股份溢價	購股權儲備	特別儲備	資本儲備	盈餘儲備	匯兌儲備	分派儲備	累計虧損	小計	非控股權益	總計
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 1 January 2019 (audited)	於二零一九年一月一日(經審核)	28,601	1,254,954	1,714	(78,256)	53,000	237,029	(263)	23,752	(1,449,004)	71,527	-	71,527
Total comprehensive income for the period (restated)	期內全面總收入(經重列)	-	-	-	-	-	-	(242)	-	146,730	146,488	7	146,495
Acquisition of subsidiaries (note 7) (restated)	收購附屬公司(附註7)(經重列)	-	-	-	-	-	-	-	-	-	-	8,032	8,032
Disposal of subsidiaries (note 8) (restated)	出售附屬公司(附註8)(經重列)	-	-	-	67,840	(53,000)	(236,752)	-	(23,752)	245,664	-	-	-
At 30 June 2019 (unaudited)	於二零一九年六月三十日(未經審核)	28,601	1,254,954	1,714	(10,416)	-	277	(505)	-	(1,056,610)	218,015	8,039	226,054
At 1 January 2020 (audited)	於二零二零年一月一日(經審核)	28,601	1,254,954	1,647	(10,416)	-	277	(736)	-	(1,094,321)	180,006	7,560	187,566
Total comprehensive income for the period	期內全面總收入	-	-	-	-	-	-	(585)	-	2,417	1,832	1,040	2,872
At 30 June 2020 (unaudited)	於二零二零年六月三十日(未經審核)	28,601	1,254,954	1,647	(10,416)	-	277	(1,321)	-	(1,091,904)	181,838	8,600	190,438

Consolidated Consolidated Statement of Cash Flows

簡明綜合現金流量表

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

		Six months ended 30 June 截至6月30日止六個月	
		2020 2020年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2019 2019年 RMB'000 人民幣千元 (Unaudited) (Restated) (經重列)
		Notes 附註	
Net cash generated from/(used in) operating activities	經營活動所得/(所用)現金淨額		3,255 (16,063)
Net cash (used in)/generated from investing activities	投資活動(所用)/所得現金淨額		(649) 5,812
Net increase/(decrease) in cash and cash equivalents	現金及現金等價物增加/(減少)淨額		2,606 (10,251)
Cash and cash equivalents at 1 January	於一月一日的現金及現金等價物		4,195 17,745
Effect of foreign exchange rates changes	外匯變動之影響		(42) (74)
Cash and cash equivalents at 30 June	於六月三十日的現金及現金等價物		6,759 7,420
Analysis of the balances of cash and cash equivalents	現金及現金等價物結餘分析		
Cash and cash equivalents at 30 June	於六月三十日的現金及現金等價物		6,759 7,420

Notes to the Unaudited Condensed Consolidated Financial Statements

未經審核簡明綜合財務報表附註

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

1. GENERAL INFORMATION

Sanai Health Industry Group Company Limited (the (“Company”) was incorporated in the Cayman Islands on 21 March 2006 and registered as an exempted company with limited liability under the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands (the (“Cayman Companies Law”) and acts as an investment holding company. Its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the (“Stock Exchange”) on 1 February 2007. The addresses of the registered office of the Company is Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands. The principal place of business of the Company is Unit 5, 7/F., Nanyang Plaza, 57 Hung To Road, Kwun Tong, Kowloon, Hong Kong.

Reference to the announcement dated on 24 January 2020, the trading of ordinary shares of the Company on the Stock Exchange has been suspended with effect from 24 January 2020. In view of the Listing (Review) Committee Decision, the Company is required to re-comply with Rule 13.24 of the Listing Rules and resume trading within a period of 18 months from the date of suspension. Should the Company fail to do so by the expiry of the 18-month period, the Stock Exchange will proceed with cancellation of the Company’s listing.

1. 一般資料

三愛健康產業集團有限公司(「本公司」)根據開曼群島公司法(「開曼群島公司法」)第22章(一九六一年第三條法例，經綜合及修訂)於二零零六年三月二十一日在開曼群島註冊成立為受豁免有限公司並登記為投資控股公司。其股份於二零零七年二月一日於香港聯合交易所有限公司(「聯交所」)主板上市。本公司的註冊辦事處地址為Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands。本公司的主要營業地點地址為香港九龍觀塘鴻圖道57號南洋廣場7樓5室。

茲提述日期為二零二零年一月二十四日之公告，本公司普通股自二零二零年一月二十四日起於聯交所暫停買賣。鑒於上市(覆核)委員會決定，本公司須重新遵守上市規則第13.24條，並於暫停買賣日期起計18個月期間內恢復買賣。倘本公司未能於18個月期間屆滿前如此行事，聯交所將取消本公司的上市地位。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

1. GENERAL INFORMATION (Continued)

Reference to the announcement dated on 8 January 2021, the Company received a letter from the Stock Exchange on 6 January 2021 in relation to resumption guidance for the Company including (i) demonstrate its compliance with Rule 13.24 of the Listing Rules; (ii) publish all outstanding financial results and address any audit modifications; and (iii) re-comply with Rules 3.10, 3.10A, 3.21 and 3.25 of the Listing Rules. The Stock Exchange may modify the Resumption Guidance that have been given and/or give further guidance if the Company's situation changes. Under Rule 6.01A of the Listing Rules, the Stock Exchange may cancel the Company's listing if trading in the Company's shares has been suspended for 18 continuous months, expiring on 23 July 2021.

1. 一般資料(續)

茲提述日期為二零二一年一月八日之公告，本公司於二零二一年一月六日收到聯交所的函件，內容有關本公司之復牌指引，包括(i)證明其遵守上市規則第13.24條；(ii)發佈所有待刊發的財務業績，並處理任何審計修訂；及(iii)重新遵守上市規則第3.10、3.10A、3.21及3.25條。倘本公司的情況有變，聯交所可能修改已發出的復牌指引及／或作出進一步指引。根據上市規則第6.01A條，倘本公司的股份已連續18個月暫停買賣(於二零二一年七月二十三日屆滿)，聯交所可將本公司除牌。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

2. BASIS OF PREPARATION

These condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard 34 “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”) and the applicable disclosures required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

These condensed consolidated financial statements should be read in conjunction with the 2019 annual financial statements. The accounting policies and methods of computation used in the preparation of these condensed consolidated financial statements are consistent with those used in the annual financial statements for the year ended 31 December 2019.

2. 編製基準

簡明綜合財務報表乃根據香港會計師公會(「香港會計師公會」)所頒佈香港會計準則第34號「中期財務報告」及香港聯合交易所有限公司證券上市規則的適用披露規定編製。

該等簡明綜合財務報表應與二零一九年年度財務報表一併閱讀。編製該等簡明綜合財務報表所用會計政策及計算方法與截至二零一九年十二月三十一日止年度的年度財務報表所用者貫徹一致。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

3. ADOPTION OF NEW AND REVISED HONG KONG FINANCIAL REPORTING STANDARDS

In the current period, the Group has adopted all the new and revised Hong Kong Financial Reporting Standards (“HKFRSs”) issued by the HKICPA that are relevant to its operations and effective for its accounting year beginning on 1 January 2020. HKFRSs comprise Hong Kong Financial Reporting Standards (“HKFRS”); Hong Kong Accounting Standards (“HKAS”); and Interpretations. The adoption of these new and revised HKFRSs did not result in significant changes to the Group’s accounting policies, presentation of the Group’s consolidated financial statements and amounts reported for the current period and prior years.

The Group has not applied the new HKFRSs that have been issued but are not yet effective. The Group has already commenced an assessment of the impact of these new HKFRSs but is not yet in a position to state whether these new HKFRSs would have a material impact on its results of operations and financial position.

3. 採納新訂及經修訂香港財務報告準則

於本期間，本集團已採納香港會計師公會頒佈的所有新訂及經修訂香港財務報告準則（「香港財務報告準則」），有關準則與其業務營運有關且於二零二零年一月一日開始的會計年度生效。香港財務報告準則包括香港財務報告準則（「香港財務報告準則」）、香港會計準則（「香港會計準則」）及詮釋。採納該等新訂及經修訂香港財務報告準則不會導致本集團會計政策、本集團綜合財務報表呈列以及本期間及過往年度所匯報金額出現重大變動。

本集團並無應用已頒佈但未生效的新訂香港財務報告準則。本集團已開始評估該等新訂香港財務報告準則之影響，惟未能確定該等新訂香港財務報告準則會否對其經營業績及財務狀況造成重大影響。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION

The Group manages its businesses by divisions, which are organised by business lines. In a manner consistent with the way in which information is reported internally to the board of the Company (the "Board") (the chief operating decision maker) for the purposes of resources allocation and performance assessment, the Group has presented the following four reportable segments. No operating segments have been aggregated to form the following reportable segments.

- (i) Pharmaceutical products: development, manufacturing, marketing and sales of pharmaceutical products, sales of pharmaceutical related software and provision of consultancy services;
- (ii) Finance leasing: provision of finance leasing services;
- (iii) Other general trading: trading of goods other than pharmaceutical products; and
- (iv) Genetic testing and molecular diagnostic services: provision of genetic testing and molecular diagnostic services.

4. 分部資料

本集團以分部管理業務，而分部則以業務範圍劃分。按與本公司董事會（「董事會」）（主要經營決策者）就資源分配和表現評估作內部報告資料一致的方式，本集團已呈列以下四個可呈報分部。本集團並無將營運分部合併以組成以下可呈報分部。

- (i) 醫藥產品：開發、製造、市場推廣及銷售醫藥產品，銷售醫藥相關軟件以及提供顧問服務；
- (ii) 融資租賃：提供融資租賃服務；
- (iii) 其他一般貿易：買賣醫藥產品以外之商品；及
- (iv) 基因檢測及分子生物診斷服務：提供基因檢測及分子生物診斷服務。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION (Continued)

Information regarding the Group's reportable segments as provided to the Board for the purposes of resources allocation and assessment of segment performance for the six months ended 30 June 2020 and 2019 is set out below:

For the six months ended 30 June 2020 (Unaudited)

4. 分部資料(續)

截至二零二零年及二零一九年六月三十日止六個月，有關本集團可呈報分部之資料載列如下，該等資料乃提供予董事會以分配資源及評估分部表現：

截至二零二零年六月三十日止六個月(未經審核)

		Continuing operations 持續經營業務				
		Pharmaceutical products	Finance leasing	Other general trading	Genetic testing and molecular diagnostic services 基因檢測及分子生物診斷服務	Total
		醫藥產品 RMB'000 人民幣千元	融資租賃 RMB'000 人民幣千元	其他一般貿易 RMB'000 人民幣千元	RMB'000 人民幣千元	總計 RMB'000 人民幣千元
Reportable segment revenue from external customers	來自外部客戶之可呈報分部收益	20,677	3,302	32,083	2,933	58,995
Reportable segment profit	可呈報分部溢利	3,572	3,072	560	67	7,271

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION (Continued)

For the six months ended 30 June 2019
(Unaudited)

4. 分部資料(續)

截至二零一九年六月三十日止六個月(未經審核)

	Discontinued operation 已終止業務		Continuing operations 持續經營業務			Total 總計
	Pharmaceutical products 醫藥產品	Pharmaceutical products 醫藥產品	Finance leasing 融資租賃	Other general trading 其他一般貿易	Genetic testing and molecular diagnostic services 基因檢測及分子生物診斷服務	
	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元

Reportable segment revenue from external customers 來自外部客戶之可呈報分部收益		28	3,102	3,239	18,951	1,370	26,690
Reportable segment profit/(loss) 可呈報分部溢利/(虧損)		(5,338)	697	797	(562)	29	(4,377)

There are no inter-segment sales for the six-month periods ended 30 June 2020 and 2019.

截至二零二零年及二零一九年六月三十日止六個月期間並無分部間銷售。

The measure used for reporting segment (loss)/profit is earnings and losses of each segment without allocation of other income, central administration costs and other operating expenses.

用作計量呈報分部(虧損)/溢利的項目為各分部的盈利及虧損，並無分配其他收入、中央行政成本及其他運營開支。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION (Continued)

(i) Revenue from external customers

The following sets out information about the geographical location of the Group's revenue from external customers, based on the location at which the services were provided or the goods delivered.

4. 分部資料(續)

(i) 來自外部客戶之收益

下表載列有關本集團來自外部客戶之收益的所在地區之資料。客戶所在地區按提供服務或貨品付運地點劃分。

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Hong Kong	香港	2,933	1,977
The PRC	中國	23,979	24,713
Europe	歐洲	32,083	-
Elimination of discontinued operation (note 8)	對銷已終止業務(附註8)	-	(28)
Revenue from continuing operations	持續經營業務收益	58,995	26,662

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION (Continued)

(ii) Reconciliation of reportable segment profit or loss:

4. 分部資料(續)

(ii) 可呈報分部損益對賬：

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Total reportable segment profit/(loss) derived from the Group's external customers	來自本集團外部客戶之可呈報分部溢利/(虧損)總額	7,271	(4,377)
Unallocated head office and corporate other revenue and net income	未分配總辦事處及公司其他收入及淨收入	787	154,941
Unallocated head office and corporate expenses	未分配總辦事處及公司開支		
— staff cost (including director's emoluments)	— 員工成本 (包括董事酬金)	(1,072)	(1,321)
— others	— 其他	(1,956)	(2,247)
Elimination of discontinued operation	對銷已終止業務	—	(147,930)
Consolidated profit/(loss) before income tax for the period from continuing operations	持續經營業務期內除所得稅前綜合溢利/(虧損)	5,030	(934)

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

4. SEGMENT INFORMATION (Continued)

(ii) Reconciliation of reportable segment profit or loss: (Continued)

The following table presents segment assets and segment liabilities of the Group's operating segments as at 30 June 2020 and 31 December 2019:

At 30 June 2020 (Unaudited)

	Pharmaceutical products	Finance leasing	Other general trading	Genetic testing and molecular diagnostic services	Total
	醫藥產品	融資租賃	其他一般貿易	基因檢測及分子生物	總額
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Reportable segment assets 可呈報分部資產	36,064	107,962	52,451	1,899	198,376
Reportable segment liabilities 可呈報分部負債	(10,865)	(16,943)	(398)	(576)	(28,782)

At 31 December 2019 (Audited)

	Pharmaceutical products	Finance leasing	Other general trading	Genetic testing and molecular diagnostic services	Total
	醫藥產品	融資租賃	其他一般貿易	基因檢測及分子生物	總額
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Reportable segment assets 可呈報分部資產	36,647	106,749	52,240	1,287	196,923
Reportable segment liabilities 可呈報分部負債	(18,019)	(12,583)	(3,799)	(199)	(34,600)

4. 分部資料(續)

(ii) 可呈報分部損益對賬:(續)

下表載列於二零二零年六月三十日及二零一九年十二月三十一日本集團經營分部的分部資產及分部負債:

於二零二零年六月三十日
(未經審核)

於二零一九年十二月三十一日
(經審核)

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

5. REVENUE

The amount of each significant category of revenue recognised during the period are as follows:

5. 收益

期內確認之各重大類別之收益金額如下：

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Revenue from contracts with customers	來自客戶合約之收益		
Sales of goods	銷售貨品		
— Pharmaceutical products	— 醫藥產品	20,677	3,130
— Other goods for general trading	— 其他一般貿易產品	32,083	18,951
Provision of genetic testing services and molecular diagnostic services	提供基因檢測及分子生物診斷服務	2,933	1,370
		55,693	23,451
Revenue from other sources	來自其他來源之收益		
Finance leasing interest income	融資租賃利息收入	3,302	3,239
		58,995	26,690
Representing:	指：		
Continuing operations	持續經營業務	58,995	26,662
Discontinued operation (note 8)	已終止業務(附註8)	—	28
		58,995	26,690

The revenue from contracts with customers of the Group during the six months ended 30 June 2020 are recognised at a point in time (for the six months ended 30 June 2019: at a point in time).

截至二零二零年六月三十日止六個月，本集團來自客戶合約之收益於某一時間點(截至二零一九年六月三十日止六個月：某一時間點)確認。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

6. PROFIT FOR THE PERIOD

Profit for the period is arrived at after charging/
(crediting):

6. 期內溢利

期內溢利已扣除／(計入)以下各項：

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
(a) Finance costs	(a) 融資成本		
Interest on bank borrowings	銀行借貸利息	—	4,162
Other interest expense	其他利息開支	—	27
Total interest expenses	利息開支總額	—	4,189
Representing:	指：		
— Continuing operations	— 持續經營業務	—	27
— Discontinued operation (note 8)	— 已終止業務 (附註8)	—	4,162
		—	4,189

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

6. PROFIT FOR THE PERIOD (Continued)

6. 期內溢利(續)

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
(b) Other items	(b) 其他項目		
Continuing operations	持續經營業務		
Depreciation of property, plant and equipment	物業、廠房及設備折舊	473	520
Amortisation of intangible assets	無形資產攤銷	985	326
Gain on financial assets at fair value through profit or loss	按公平值計入損益之金融資產的收益	(11)	(186)
Expenses relating to short-term leases	有關短期租賃之開支	457	1,000
Cost of inventories	存貨成本	43,825	21,480
Discontinued operation (note 8)	已終止業務(附註8)		
Other staff costs	其他員工成本		
— Salaries, wages and other benefits	— 薪金、工資及其他福利	—	1,076
Total staff costs	總員工成本	—	1,076
Cost of inventories	存貨成本	—	279

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

7. ACQUISITION OF SUBSIDIARIES For the six months ended 30 June 2019

(a) Acquisition of Fujian Yongchun Pharmaceutical Company Limited ("Fujian Yongchun")

On 25 October 2018, the Group entered into a sales and purchase agreement with an independent third party to acquire 51% equity interest in Fujian Yongchun at a consideration of RMB7,650,000 which shall be settled by cash. The principal activities of Fujian Yongchun are production, development and sales of pharmaceutical products in the PRC. The management considers that such acquisition will enable the Group to increase new manufacturing bases of pharmaceutical products and enrich product categories as well as expand sales network. The acquisition was completed on 28 March 2019.

The consideration amounted to RMB7,650,000 is payable to the vendor.

(b) Acquisition of Fujian Zhixin Medicine Co., Limited ("Fujian Zhixin")

On 29 March 2019, the Group entered into a sales and purchase agreement with an independent third party to acquire entire equity interest in Fujian Zhixin at a consideration of RMB2,000,000 which shall be settled by cash. The principal activities of Fujian Zhixin are sales of pharmaceutical products in the PRC. The management considers that such acquisition will enable the Group to enrich product categories as well as expand sales network. The acquisition was completed on 1 April 2019.

7. 收購附屬公司

截至二零一九年六月三十日止六個月

(a) 收購福建永春製藥有限公司 (「福建永春」)

於二零一八年十月二十五日，本集團與獨立第三方訂立買賣協議，以代價人民幣7,650,000元收購福建永春51%股權，並以現金結清。福建永春的主要業務為在中國生產、開發及銷售醫藥產品。管理層認為此項收購將使本集團增加新的醫藥產品生產基地，豐富產品類別及擴大銷售網絡。此項收購已於二零一九年三月二十八日完成。

代價人民幣7,650,000元已支付予賣方。

(b) 收購福建至信醫藥有限公司 (「福建至信」)

於二零一九年三月二十九日，本集團與獨立第三方訂立買賣協議，以代價人民幣2,000,000元收購福建至信全部股權，並以現金結清。福建至信的主要業務為在中國銷售醫藥產品。管理層認為此項收購將豐富本集團產品類別及擴大銷售網絡。此項收購已於二零一九年四月一日完成。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

7. ACQUISITION OF SUBSIDIARIES (Continued)

For the six months ended 30 June 2019 (Continued)

(c) Acquisition of Zentrogene Bioscience Laboratory Limited ("Zentrogene")

On 29 March 2019, the Group entered into a sales and purchase agreement with an independent third party to acquire entire equity interest in Zentrogene at a consideration of HK\$19,500,000 (approximately RMB16,673,000) which shall be settled by cash. The principal activities of Zentrogene are provision of genetic testing and molecular diagnostic services in Hong Kong. The management considers that such acquisition will enable the Group to develop its precision medicine. The acquisition was completed on 1 April 2019.

Portion of the consideration amounted to approximately RMB2,763,000 had been settled by cash during the year ended 31 December 2019. The Group had settled the remaining portion of the consideration amounted to approximately RMB13,910,000 through a non-cash transaction.

7. 收購附屬公司(續)

截至二零一九年六月三十日止六個月(續)

(c) 收購 Zentrogene Bioscience Laboratory Limited (「Zentrogene」)

於二零一九年三月二十九日，本集團與獨立第三方訂立買賣協議，以代價19,500,000港元(約人民幣16,673,000元)收購Zentrogene全部股權，並以現金結清。Zentrogene的主要業務為在香港提供基因檢測及分子生物診斷服務。管理層認為此項收購將使本集團發展其精準醫學業務。此項收購已於二零一九年四月一日完成。

截至二零一九年十二月三十一日止年度，部分代價約人民幣2,763,000元已以現金結清。本集團已透過非現金交易結清代價餘款約人民幣13,910,000元。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

7. ACQUISITION OF SUBSIDIARIES (Continued)

For the six months ended 30 June 2019 (Continued)

(c) Acquisition of Zentrogene (Continued)

The following summarises the total consideration and the assets acquired and liabilities assumed and goodwill arising from the acquisition of Fujian Yongchun, Fujian Zhixin and Zentrogene at their acquisition dates:

7. 收購附屬公司(續)

截至二零一九年六月三十日止六個月(續)

(c) 收購 Zentrogene (續)

收購福建永春、福建至信及 Zentrogene 於各自收購日期之總代價、所收購資產及所承擔負債以及所產生商譽概述如下：

	(a) Fujian Yongchun 福建永春 As at 28 March 2019 於 二零一九年 三月二十八日 RMB'000 人民幣千元	(b) Fujian Zhixin 福建至信 As at 1 April 2019 於 二零一九年 四月一日 RMB'000 人民幣千元	(c) Zentrogene Zentrogene As at 1 April 2019 於 二零一九年 四月一日 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元	
Net assets acquired:	所收購淨資產：				
Property, plant and equipment	物業、廠房及設備	9,280	105	550	9,935
Right-of-use assets	使用權資產	4,756	-	-	4,756
Intangible assets	無形資產	11,753	16	2,717	14,486
Deferred tax assets	遞延稅項資產	1,555	-	-	1,555
Inventories	存貨	679	176	-	855
Trade and other receivables	貿易應收款項及其他 應收款項	33	4,860	954	5,847
Tax recoverable	可收回稅項	-	-	106	106
Cash and cash equivalents	現金及現金等價物	487	35	388	910
Trade and other payables	貿易應付款項及其他 應付款項	(9,212)	(3,149)	(508)	(12,869)
Deferred tax liabilities	遞延稅項負債	(2,938)	-	(448)	(3,386)
Total identifiable net assets at fair value	按公平值列賬之可 識別淨資產總額	16,393	2,043	3,759	22,195
Non-controlling interest	非控股權益	(8,032)	-	-	(8,032)
Goodwill	商譽	-	-	12,914	12,914
Gain on bargain purchase on acquisition	收購之議價購買收益	(711)	(43)	-	(754)
Total consideration	總代價	7,650	2,000	16,673	26,323

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

8. DISCONTINUED OPERATION AND DISPOSAL OF SUBSIDIARIES For the six months ended 30 June 2019

Disposal of Wuyi International Pharmaceutical (Hong Kong) Company Limited ("Wuyi HK") and Fujian Sanai Pharmaceutical Company Limited ("Fujian Sanai")

On 30 April 2019, the Group disposed of the entire equity interest of Wuyi HK and Fujian Sanai with consideration of approximately RMB9,000 where Wuyi HK engaged in investment holding and Fujian Sanai engaged in investment holding, develop, manufacture, marketing and sales of pharmaceutical products. Wuyi HK did not carried out any business during the period. The disposal was completed on 30 April 2019 ("2019 Disposal Date") and the Group discontinued its development, manufacturing, marketing and sales of pharmaceutical products business under Fujian Sanai.

(a) Analysis of the profit from the discontinued operation

8. 已終止業務及出售附屬公司 截至二零一九年六月三十日止六個月

出售武夷國際藥業(香港)有限公司(「武夷香港」)及福建三愛藥業有限公司(「福建三愛」)

於二零一九年四月三十日，本集團出售武夷香港及福建三愛全部股權，代價為約人民幣9,000元，其中武夷香港從事投資控股，而福建三愛從事投資控股、開發、製造、市場推廣及銷售醫藥產品。於期內，武夷香港並無開展任何業務。此項出售已於二零一九年四月三十日(「二零一九年出售日期」)完成，而本集團已終止其福建三愛之開發、製造、市場推廣及銷售醫藥產品業務。

(a) 已終止業務溢利分析

	2019 2019年 RMB'000 人民幣千元
Profit for the period from discontinued operation	35,939
Gain on disposal of subsidiaries (note 8(b))	111,991
	147,930

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

8. DISCONTINUED OPERATION AND DISPOSAL OF SUBSIDIARIES (Continued)

For the six months ended 30 June 2019 (Continued)

Disposal of Wuyi HK and Fujian Sanai (Continued)

- (a) Analysis of the profit from the discontinued operation (Continued)

8. 已終止業務及出售附屬公司 (續)

截至二零一九年六月三十日止六個月(續)

出售武夷香港及福建三愛(續)

- (a) 已終止業務溢利分析(續)

		Period from 1 January 2019 to 2019 Disposal Date Fujian Sanai 自二零一九年 一月一日至 二零一九年 出售日期 止期間 福建三愛 RMB'000 人民幣千元
Revenue	收益	28
Cost of sales and services rendered	銷售及提供服務之成本	(279)
Gross loss	毛虧	(251)
Other income and other gain/losses, net	其他收入及其他收益/虧損淨額	43,277
Distribution costs	分銷成本	(7)
Administrative and other expenses	行政及其他開支	(934)
Finance costs	融資成本	(4,162)
Impairment loss on trade receivables	貿易應收款項減值虧損	(1,664)
Impairment loss on other receivables	其他應收款項減值虧損	(320)
Profit before income tax	除所得稅前溢利	35,939
Income tax expenses	所得稅開支	-
Profit for the period from discontinued operation	已終止業務期內溢利	35,939

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

8. DISCONTINUED OPERATION AND DISPOSAL OF SUBSIDIARIES (Continued)

For the six months ended 30 June 2019 (Continued)

Disposal of Wuyi HK and Fujian Sanai (Continued)

(b) Disposal of subsidiaries

8. 已終止業務及出售附屬公司(續)

截至二零一九年六月三十日止六個月(續)

出售武夷香港及福建三愛(續)

(b) 出售附屬公司

	At 2019 Disposal Date 於二零一九年 出售日期 2019 Total 二零一九年 總計 RMB'000 人民幣千元
Net liabilities disposed of	
Property, plant and equipments	8
Inventories	2,032
Trade and other receivables	84,488
Tax recoverable	302
Amount due from group companies	2,239
Cash and cash equivalents	30
Trade and other payables	(30,061)
Secured bank loans	(165,989)
Deferred tax liabilities	(5,031)
	(111,982)
Gain on disposal of subsidiaries	111,991
Total consideration	9

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

9. INCOME TAX EXPENSES

9. 所得稅開支

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Current tax	當期稅項		
PRC Enterprise Income Tax ("EIT")	中國企業所得稅 ([「企業所得稅」])	1,818	341
		1,818	341
Deferred taxation	遞延稅項	(245)	(82)
		1,573	259
Representing:	指：		
— Continuing operations	— 持續經營業務	1,573	259

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

9. INCOME TAX EXPENSES (Continued)

For the PRC subsidiaries of the Group, PRC EIT is calculated at 25% (2019: 25%) in accordance with the relevant laws and regulations in the PRC.

Hong Kong Profits Tax has been provided at a rate of 16.5% on the estimated assessable profit for the six months ended 30 June 2020 and 2019. No provision for Hong Kong Profits Tax has been made for the six months ended 30 June 2020 and 2019 as the Group did not generate any assessable profits arising in Hong Kong during the six months ended 30 June 2020 and 2019.

Pursuant to the rules and regulations of the Cayman Islands, the Group is not subject to any income tax in the Cayman Islands.

10. DIVIDENDS

The directors do not recommend the payment of any dividend for the six months ended 30 June 2020 and 2019.

9. 所得稅開支(續)

就本集團中國附屬公司而言，中國企業所得稅乃根據中國相關法律及法規按25%（二零一九年：25%）的稅率計算。

香港利得稅撥備乃根據截至二零二零年及二零一九年六月三十日止六個月估計應課稅溢利按16.5%的稅率計提。截至二零二零年及二零一九年六月三十日止六個月概無就香港利得稅計提撥備，原因為本集團截至二零二零年及二零一九年六月三十日止六個月於香港概無產生任何應課稅溢利。

根據開曼群島之規則及規例，本集團毋須繳付任何開曼群島所得稅。

10. 股息

董事不建議就截至二零二零年及二零一九年六月三十日止六個月派付任何股息。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

11. EARNINGS/(LOSS) PER SHARE

The calculation of basis earnings/(loss) per share attributable to the owners of the Company are based on the following data:

11. 每股盈利/(虧損)

本公司擁有人應佔每股基本盈利/(虧損)乃根據以下數據計算：

		Six months ended 30 June	
		截至6月30日止六個月	
		2020	2019
		2020年	2019年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Profit/(loss) for the year attributable to the owners of the Company for the purpose of basic earnings/(loss) per share	就計算每股基本盈利/(虧損)所用本公司擁有人應佔年內溢利/(虧損)		
— From continuing operations	— 持續經營業務	2,417	(1,200)
— From discontinued operation	— 已終止業務	-	147,930
		2,417	146,730
Number of shares		'000	'000
股份數目		千股	千股
Weighted average number of ordinary shares for the purpose of basic earnings/(loss) per share	就計算每股基本盈利/(虧損)所用普通股加權平均數	3,067,223	3,067,223

For the period ended 30 June 2020 and 2019, the dilutive earnings/(loss) per share was the same as the basic earnings/(loss) per share as the impact of share options had an anti-dilutive effect.

截至二零二零年及二零一九年六月三十日止期間，每股攤薄盈利/(虧損)與每股基本盈利/(虧損)金額相同，原因為購股權具有反攤薄影響。

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

12. TRADE AND OTHER RECEIVABLES

12. 貿易應收款項及其他應收款項

		As at 30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at 31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Trade receivables (net of loss allowance)	貿易應收款項 (扣除虧損撥備)	6,432	13,283
Other receivables	其他應收款項	20,572	17,270
Investment in bond issued by a private company	投資私營公司發行之債券	11,850	11,622
Amount due from a related company	應收一間關連公司款項	2	2
Prepayments and deposits	預付款項及按金	72,191	46,868
Other PRC tax receivables	其他中國應收稅項	100	1,249
		111,147	90,294
Represented by:	指：		
Current	即期	111,147	66,589
Non-current	非即期	-	23,705
		111,147	90,294

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

12. TRADE AND OTHER RECEIVABLES (Continued)

The Group normally grants credit terms of 30 to 180 days (31 December 2019: 30 to 180 days) to its customers. Included in trade and other receivables are trade receivables (net of impairment) of approximately RMB6,432,000 (31 December 2019: approximately RMB13,283,000) and their ageing analysis (net of impairment) at the end of the reporting period, presented based on the invoice date is as follows:

12. 貿易應收款項及其他應收款項 (續)

本集團一般向其客戶授出30至180日(二零一九年十二月三十一日:30至180日)的信貸期。貿易應收款項及其他應收款項當中包含貿易應收款項(扣除減值)約人民幣6,432,000元(二零一九年十二月三十一日:約人民幣13,283,000元)。於報告期末按發票日期呈列的賬齡分析(扣除減值)如下:

		As at 30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at 31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Within 30 days	30日內	1,676	5,333
31 to 60 days	31至60日	913	1,553
61 to 90 days	61至90日	399	316
91 to 120 days	91至120日	115	802
121 to 365 days	121至365日	1,113	3,527
Over 365 days	超過365日	2,216	1,752
		6,432	13,283

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

13. TRADE AND OTHER PAYABLES

13. 貿易應付款項及其他應付款項

		As at 30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at 31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Trade payables	貿易應付款項	5,626	6,303
Payroll and welfare payables	應付薪金及福利	1,234	1,553
Accrued expenses	應計費用	5,705	8,836
Other payables	其他應付款項	37,021	36,424
Other PRC tax payables	其他中國應付稅項	126	229
Contract liabilities	合約負債	25,517	3,104
Deposits received	已收按金	5,800	5,800
		81,029	62,249

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

13. TRADE AND OTHER PAYABLES (Continued)

Included in trade and other payables are trade payables of approximately RMB5,626,000 (31 December 2019: approximately RMB6,303,000) and their ageing analysis of trade payables, presented based on the invoice date is as follows:

13. 貿易應付款項及其他應付款項 (續)

貿易應付款項及其他應付款項當中包含貿易應付款項約人民幣5,626,000元(二零一九年十二月三十一日:約人民幣6,303,000元)·按發票日期呈列的貿易應付款項賬齡分析如下:

		As at 30 June 2020 於2020年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at 31 December 2019 於2019年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Within 30 days	30日內	2,560	3,941
31 to 60 days	31至60日	27	239
61 to 90 days	61至90日	320	54
91 to 120 days	91至120日	1,477	33
121 to 365 days	121至365日	900	1,992
Over 365 days	超過365日	342	44
		5,626	6,303

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月

14. SHARE CAPITAL

14. 股本

	Number of ordinary shares 普通股數目 (‘000) (千股)	Amount 金額 HK\$’000 千港元
--	--	---------------------------------

Authorised:

Ordinary shares of HK\$0.01 each
At 1 January 2019 (Audited),
30 June 2019 (Unaudited),
1 January 2020 (Audited) and
30 June 2020 (Unaudited)

法定：

每股面值0.01港元的普通股
於二零一九年一月一日(經審核)、
二零一九年
六月三十日(未經審核)、
二零二零年一月一日(經審核)
及二零二零年
六月三十日(未經審核)

10,000,000 100,000

Issued and fully paid:

Ordinary shares of HK\$0.01 each
At 1 January 2019 (Audited),
30 June 2019 (Unaudited),
1 January 2020 (Audited) and
30 June 2020 (Unaudited)

已發行及繳足：

每股面值0.01港元的普通股
於二零一九年一月一日(經審核)、
二零一九年
六月三十日(未經審核)、
二零二零年一月一日(經審核)
及二零二零年
六月三十日(未經審核)

3,067,223 30,672

RMB’000
人民幣千元

Shown in the condensed consolidated financial statements at 1 January 2019 (Audited), 30 June 2019 (Unaudited), 1 January 2020 (Audited) and 30 June 2020 (Unaudited)

於二零一九年一月一日(經審核)、
二零一九年六月三十日(未經審核)、
二零二零年一月一日(經審核)及
二零二零年六月三十日(未經審核)
之簡明綜合財務報表所列

28,601

Notes to the Unaudited Condensed Consolidated Financial Statements (Continued)

未經審核簡明綜合財務報表附註(續)

For the six months ended 30 June 2020

截至二零二零年六月三十日止六個月

15. MATERIAL RELATED PARTY TRANSACTIONS

The details of remuneration of key management personnel, representing amounts paid to the directors of the Company during the six-month period ended 30 June 2020, are set out as follows:

15. 重大關連方交易

截至二零二零年六月三十日止六個月期間的主要管理人員薪酬(即向本公司董事支付的金額)詳情載列如下:

	Six months ended 30 June	
	截至6月30日止六個月	
	2020	2019
	2020年	2019年
	RMB'000	RMB'000
	人民幣千元	人民幣千元
	(Unaudited)	(Unaudited)
	(未經審核)	(未經審核)
Short-term employee benefits 短期僱員福利	840	627



Sanai Health Industry Group Company Limited
三愛健康產業集團有限公司